205 related articles for article (PubMed ID: 29171986)
21. Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer.
Enkhbat T; Nishi M; Takasu C; Yoshikawa K; Jun H; Tokunaga T; Kashihara H; Ishikawa D; Shimada M
Anticancer Res; 2018 Jun; 38(6):3367-3373. PubMed ID: 29848685
[TBL] [Abstract][Full Text] [Related]
22. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study.
Wang L
J Ovarian Res; 2019 Apr; 12(1):37. PubMed ID: 31039792
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
[TBL] [Abstract][Full Text] [Related]
24. Association of a
Venugopal G; O'Regan NL; Babu S; Schumann RR; Srikantam A; Merle R; Hartmann S; Steinfelder S
Am J Trop Med Hyg; 2019 Feb; 100(2):344-350. PubMed ID: 30594267
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
26. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
27. Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer.
Chatterjee J; Dai W; Aziz NHA; Teo PY; Wahba J; Phelps DL; Maine CJ; Whilding LM; Dina R; Trevisan G; Flower KJ; George AJT; Ghaem-Maghami S
Clin Cancer Res; 2017 Jul; 23(13):3453-3460. PubMed ID: 27986748
[No Abstract] [Full Text] [Related]
28. Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
Xue C; Xu Y; Ye W; Xie Q; Gao H; Xu B; Zhang D; Jiang J
Gynecol Oncol; 2020 Apr; 157(1):222-233. PubMed ID: 31987601
[TBL] [Abstract][Full Text] [Related]
29. The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer.
Qu QX; Huang Q; Shen Y; Zhu YB; Zhang XG
Tumour Biol; 2016 Apr; 37(4):5031-7. PubMed ID: 26541760
[TBL] [Abstract][Full Text] [Related]
30. The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
Zhu X; Zhao L; Lang J
Int J Gynecol Cancer; 2018 Oct; 28(8):1514-1519. PubMed ID: 30045136
[TBL] [Abstract][Full Text] [Related]
31. Programmed death-ligand 1 single nucleotide polymorphism affects breast cancer chemosensitivity and adverse events in the neoadjuvant setting.
Lu J; Wu Z; Peng J; Xu S; Zhou L; Lin Y; Wang Y; Yin W; Lu J
Int J Biol Markers; 2020 Sep; 35(3):90-101. PubMed ID: 33073683
[TBL] [Abstract][Full Text] [Related]
32. Association of PD-1 and PDL-1 gene polymorphisms with colorectal cancer risk and prognosis.
Cevik M; Namal E; Iner-Koksal U; Dinc-Sener N; Karaalp A; Ciftci C; Susleyici B
Mol Biol Rep; 2022 Mar; 49(3):1827-1836. PubMed ID: 35076848
[TBL] [Abstract][Full Text] [Related]
33. Common inherited variants of PDCD1, CD274 and HAVCR2 genes differentially modulate the risk and prognosis of adenocarcinoma and squamous cell carcinoma.
Moksud N; Wagner M; Pawełczyk K; Porębska I; Muszczyńska-Bernhard B; Kowal A; Wiśniewski A; Kosacka M; Kończak J; Karpiński P; Frydryk D; Andrzejczak A; Karabon L; Kuśnierczyk P; Jasek M
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6381-6390. PubMed ID: 36759392
[TBL] [Abstract][Full Text] [Related]
34. PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.
Bi Y; Ren X; Bai X; Meng Y; Luo Y; Cao J; Zhang Y; Liang Z
Eur J Surg Oncol; 2019 Mar; 45(3):353-358. PubMed ID: 30528043
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients.
Ito S; Fukagawa T; Noda M; Hu Q; Nambara S; Shimizu D; Kuroda Y; Eguchi H; Masuda T; Sato T; Katai H; Sasako M; Mimori K
Ann Surg Oncol; 2018 Nov; 25(12):3755-3763. PubMed ID: 30203407
[TBL] [Abstract][Full Text] [Related]
36. [Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids].
Li M; Xu S; Fan H; Zhang H; Li Y; Li Y; Liu M; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):847-853. PubMed ID: 27978870
[TBL] [Abstract][Full Text] [Related]
37. Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer.
Høgdall E; Høgdall C; Vo T; Zhou W; Huang L; Marton M; Keefe SM; Busch-Sørensen M; Sørensen SM; Georgsen J; Mejlgaard E; Nedergaard L; Steiniche T
Int J Gynecol Cancer; 2020 Jul; 30(7):1034-1042. PubMed ID: 32527769
[TBL] [Abstract][Full Text] [Related]
38. Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer.
Lee SY; Jung DK; Choi JE; Jin CC; Hong MJ; Do SK; Kang HG; Lee WK; Seok Y; Lee EB; Jeong JY; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
Gene; 2017 Jan; 599():28-35. PubMed ID: 27838455
[TBL] [Abstract][Full Text] [Related]
39. Associations of PD-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract][Full Text] [Related]
40. The blockage signal for PD-L1/CD274 gene variants and their potential impact on lung carcinoma susceptibility.
Sakran MI; Alalawy AI; Alharbi AA; El-Hefnawy ME; Alzahrani SM; Alfuraydi A; Alzuaibr FM; Zidan NS; Elsaid AM; Toraih EA; Elshazli RM
Int Immunopharmacol; 2023 Dec; 125(Pt A):111180. PubMed ID: 37939515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
